A detailed history of Palisades Hudson Asset Management, L.P. transactions in Abb Vie Inc. stock. As of the latest transaction made, Palisades Hudson Asset Management, L.P. holds 3,746 shares of ABBV stock, worth $622,884. This represents 0.31% of its overall portfolio holdings.

Number of Shares
3,746
Previous 4,143 9.58%
Holding current value
$622,884
Previous $711,000 4.08%
% of portfolio
0.31%
Previous 0.33%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$163.84 - $199.33 $65,044 - $79,134
-397 Reduced 9.58%
3,746 $740,000
Q4 2023

Feb 12, 2024

SELL
$137.6 - $154.97 $412 - $464
-3 Reduced 0.07%
4,143 $642,000
Q4 2022

Feb 08, 2023

SELL
$138.31 - $165.87 $138 - $165
-1 Reduced 0.02%
4,146 $670,000
Q3 2022

Oct 28, 2022

SELL
$134.21 - $153.93 $61,602 - $70,653
-459 Reduced 9.97%
4,147 $556,000
Q2 2022

Aug 10, 2022

BUY
$137.62 - $174.96 $63,305 - $80,481
460 Added 11.1%
4,606 $705,000
Q1 2022

Apr 27, 2022

BUY
$131.98 - $163.75 $3,167 - $3,930
24 Added 0.58%
4,146 $672,000
Q1 2021

May 10, 2021

SELL
$102.3 - $112.62 $22,915 - $25,226
-224 Reduced 5.15%
4,122 $446,000
Q4 2020

Jan 29, 2021

BUY
$80.49 - $108.67 $16,097 - $21,734
200 Added 4.82%
4,346 $465,000
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $16,141 - $21,599
220 Added 5.6%
4,146 $407,000
Q1 2019

Apr 23, 2019

SELL
$77.14 - $90.79 $72,203 - $84,979
-936 Reduced 19.25%
3,926 $316,000
Q3 2018

Nov 08, 2018

SELL
$88.91 - $98.84 $1,244 - $1,383
-14 Reduced 0.29%
4,862 $460,000
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $94,038 - $103,120
-1,050 Reduced 17.72%
4,876 $472,000
Q3 2017

Nov 06, 2017

BUY
$69.85 - $89.22 $413,931 - $528,717
5,926
5,926 $527,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $294B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Palisades Hudson Asset Management, L.P. Portfolio

Follow Palisades Hudson Asset Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palisades Hudson Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Palisades Hudson Asset Management, L.P. with notifications on news.